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Purpose. To investigate degradation kinetics of oxytocin as a function of temperature and pH, and
identify the degradation products.
Materials and Methods. Accelerated degradation of oxytocin formulated at pH 2.0, 4.5, 7.0 and 9.0 was
performed at 40, 55, 70 and 80°C. Degradation rate constants were determined from RP-HPLC data.
Formulations were characterized by HP-SEC, UV absorption and ﬂuorescence spectroscopy. Degradation
products were identiﬁed by ESI-MS/MS.
Results. The loss of intact oxytocin in RP-HPLC was pH- and temperature-dependent and followed
(pseudo) ﬁrst order kinetics. Degradation was fastest at pH 9.0, followed by pH 7.0, pH 2.0 and pH 4.5.
The Arrhenius equation proved suitable to describe the kinetics, with the highest activation energy
(116.3 kJ/mol) being found for pH 4.5 formulations. At pH 2.0 deamidation of Gln
4, Asn
5, and Gly
9-NH2,
as well as combinations thereof were found. At pH 4.5, 7.0 and 9.0, the formation of tri- and tetrasulﬁde-
containing oxytocin as well as different types of disulﬁde and dityrosine-linked dimers were found to
occur. Beta-elimination and larger aggregates were also observed. At pH 9.0, mono-deamidation of Gln
4,
Asn
5, and Gly
9-NH2 additionally occurred.
Conclusions. Multiple degradation products of oxytocin have been identiﬁed unequivocally, including
various deamidated species, intramolecular oligosulﬁdes and covalent aggregates. The strongly pH
dependent degradation can be described by the Arrhenius equation.
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INTRODUCTION
Oxytocin is a nonapeptidic hormone that is released
from the posterior lobe of the pituitary gland of the
hypothalamus. Therapeutically, it is used to induce or
stimulate labor (1) and to prevent post-partum hemorrhage,
which is a major cause of birth related maternal deaths in
developing countries (2). In 1993 and 1994, the World Health
Organization (WHO) supported a number of studies which
demonstrated that oxytocin loses potency in ﬁeld conditions,
in particular in tropical climates (3,4). Prompted by the
WHO, a program was initiated recently by Top Institute
Pharma (The Netherlands) entitled: Hot medicines—breaking
the cold chain requirement for polypeptide-based priority
medicines. The principal aim of this project is the rapid
development of heat-stable oxytocin formulations in addition
to several other peptide/protein-based priority medicines for
diseases including hepatitis B, diabetes and inﬂuenza. Integral
to this work is the development of new analytical methods.
In order to be able to apply a scientiﬁc and intelligent
approach to formulation development, a thorough knowledge
of drug stability and degradation pathways is essential.
Currently, there are only limited data available on oxytocin
degradation and stability, despite oxytocin being a well-
known and extensively studied peptide hormone. Almost
30 years ago, it was shown by Nachtmann et al. (1981) that
oxytocin is most stable between pH 3 and 5, but only limiting
data on degradation kinetics were given (5). In the following
years, no relevant publications on degradation kinetics and
pathways of oxytocin were published.
Because of the role oxytocin plays in the function of the
central nervous system, research on its clinical application to
treat anxiety- and depression-related diseases, as well as several
neuropsychiatric disorders, including autism, obsessive-
compulsive disorder, eating disorders and addiction is ongoing
(6,7).Thesenewﬁeldsofapplicationmightalsorequirenewand
innovative oxytocin formulations.
Oxytocin consists of a six amino acid ring (Cys
1,T y r
2,
Ile
3, Gln
4, Asn
5, Cys
6) and a tail of three amino acids (Pro
7,
Leu
8,G l y
9-NH2). Asn
5 and Tyr
2 are the key moieties
required for proper function at the active site of the uterine
receptor and Ile
3, Gln
4, Pro
7 and Leu
8 are important for
receptor binding (8). Any changes in the structure caused by
chemical or physical instabilities can lead to loss of afﬁnity to
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inspection of the amino acid sequence and chemical
structure of oxytocin several sites are evident, which could be
susceptible to degradation via deamidation, oxidation or thiol
exchange. Gln
4 and Asn
5 within the macrocycle and the
amidated C-terminal amino acid Gly
9-amide are predisposed
to deamidation. Under acidic conditions deamidation occurs
mainly via acid catalyzed hydrolysis, i.e. RCONH2 ⇒ RCOOH
(9). Hydrolysis at low pH can also cause fragmentation. Under
neutral and alkaline conditions, deamidation proceeds via the
formation of cyclic imide intermediates (9–11). Tyr
2 and Cys
1,6
are susceptible to oxidation, activated for example by the
presence of oxygen, light and/or metal ions. A further
consideration for oxytocin is the stability of its Cys
1-Cys
6
disulﬁde bridge with respect to thiol exchange. At neutral and
alkaline conditions this occurs via nucleophilic attack of free
thiolate on one of the sulfur atoms within the disulﬁde bridge.
At low pH the disulﬁde exchange progresses via a sulfenium
cation, formed following protonation of the disulﬁde bridge
(9,12). In either case disulﬁde exchange can result in
dimerization and progressive aggregation. Surprisingly, there
is no detailed information about oxytocin degradation in
therapeutic formulations available in the literature; this
provoked us to undertake the study presented herein.
Our ﬁrst objective was to analyze the kinetics of oxytocin
degradation as a function of pH and temperature, an important
step towards being able to predict the long-term stability of
oxytocin at relevant storage temperatures. The second aim was
to identify the degradation products and obtain insights into
the degradation pathways, which would facilitate the rational
design of heat-stable oxytocin formulations. In order to be able
to identify and separate the various degradation products an
optimized gradient RP-HPLC method was developed, based on
the European Pharmacopoeia (13) and on the isocratic method
described by Chaibva and Walker (14). In combination with
high-resolution mass spectrometry, this enabled the identiﬁca-
tion ofthemaindegradation productsandprovidedmechanistic
insight into the pathways leading to oxytocin degradation.
MATERIALS AND METHODS
Materials
Oxytocinacetatepowder(Diosynth,Oss,TheNetherlands)
was dissolved in 50 mM phosphate buffer pH 2.0, 4.5, 7.0 and
9.0. The exact concentration was determined by UVabsorption
spectroscopy, using an extinction coefﬁcient at 280 nm of
1.52 ml mg
−1 cm
−1 based on Gill and Hippel (15). The
formulation buffers were prepared at a concentration of
50 mM using NaH2PO4*2H2O (Fluka, Zwijndrecht, The
Netherlands), Na2HPO4*2H2O (Fluka, Zwijndrecht, The
Netherlands) and ortho-phosphoric acid (Merck, Amsterdam,
TheNetherlands).All buffers wereﬁltered through 0.2μm pore
PES-ﬁlters (Millipore, Amsterdam, The Netherlands). For
HPLC analytics, HPLC grade acetonitrile (ACN) and formic
acid were used.
Accelerated Stability Study of Oxytocin
Oxytocin was formulated at a concentration of 0.1 mg/ml
in 50 mM phosphate at each of pH 2.0, 4.5, 7.0 and 9.0. About
9 ml of each formulation were stored in 10R glass type I vials
either at 40°C in a stove or at 55°C, 70°C or 80°C in water
baths of constant temperature. To study the concentration
dependency of oxytocin degradation, control experiments at
70°C were performed for all pH conditions at oxytocin
concentrations of 0.02, 0.1 and 0.5 mg/ml. The extent of
degradation in each case was quantiﬁed by monitoring the
disappearance of the main peak by RP-HPLC corresponding
to oxytocin. During the stability studies the pH values of the
formulations were controlled. They remained within ±0.1 pH
units for pH 2.0, 7.0 and 9.0 formulations, and within ±0.2 pH
units for pH 4.5 formulations.
UV Absorption Spectroscopy
UV spectroscopy was performed with an Agilent 8453
UV/VIS spectrometer (Agilent, Waldbronn, Germany). Two
ml of the oxytocin solutions were measured in quartz cuvettes
with a path length of 10 mm and the particular buffer spectrum
subtracted. Spectra were recorded from 240 to 340 nm.
Fluorescence Spectroscopy
Steady state ﬂuorescence spectra were measured with an
FS920 ﬂuorescence spectrometer (Edinburgh Instruments,
Edinburgh, Scotland) in 96-well plates. To detect the forma-
tion of dityrosine, the undiluted formulations were measured
using an excitation wavelength of 340 nm, emission and
excitation slits of 5 nm, a dwell time of 0.5 s, steps of 0.5 nm
and a cumulative addition of two scans for each spectrum.
The spectra were corrected by subtracting the buffer spectra,
measured under the same conditions.
Reversed Phase High Pressure Liquid Chromatography
(RP-HPLC)
RP-HPLC was performed using an Alltima C18 RP-
column, 5 μm particle size, inner diameter of 4.6 mm and
length of 150 mm (Alltech, Ridderkerk, Netherlands), a
Waters 600 controller with gradient pump, a Waters 717
autosampler, a Waters 2487 UV detector and helium sparge
equipment (Waters, Milford Massachusetts, USA). Twenty μl
of the samples were injected and the measurements were
performed at a ﬂow rate of 1.0 ml/min and UV detection at
220 nm and 280 nm. Gradient elution with 15% (v/v) ACN in
65 mM phosphate buffer pH 5.0 as solvent A and 60% (v/v)
acetonitrile in 65 mM phosphate buffer pH 5.0 as solvent B
was used. Within the gradient the ACN concentration was
linearly increased from 15% at the beginning, to 20% at
10 min, to 30% at 20 min and ﬁnally to 60% at 25 min.
Subsequently, the ACN concentration was lowered to 15%
within 0.1 min and equilibrated for 10 min prior to the next
injection. To determine the oxytocin concentration by RP-
HPLC, a calibration curve with three oxytocin standards of
known concentration (0.05, 0.1 and 0.15 mg/ml oxytocin when
analyzing 0.1 mg/ml OT formulations) determined by UV
absorption spectroscopy was prepared. Precision, linearity,
limit of detection and limit of quantiﬁcation of the method
were determined according to the ICH guideline (16).
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Size exclusion chromatography was performed using a
Superdex peptide 10/300 GL column (GE Healthcare Inc.,
Brussels, Belgium) on an isocratic HPLC system with a
Waters 515 pump, a Waters 717 plus autosampler, a Waters
474 ﬂuorescence detector (Waters, Milford Massachusetts,
USA) and a Shimadzu SPD UV/Vis detector (Shimadzu,
Tokyo, Japan). Fifty μl were injected and separation was
performed at a ﬂow rate of 0.5 ml/min. Peaks were detected
by UVabsorption at 274 nm, as well as ﬂuorescence detection
working with an excitation wavelength of 274 nm and
emission wavelength of 310 nm. Different mobile phases
were evaluated for the separation: 50 mM phosphate with
150 mM NaCl, pH 2.0 or 5.0, and 30% ACN with 70% 0.04 M
formic acid.
High Resolution Mass Spectrometry (MS)
All MS experiments were conducted in positive ion mode
on a LTQ OrbitrapXL (Thermo Scientiﬁc, Bremen, Germany).
For MS/MS experiments a normalized collision energy of 35%
was used, the activation time was set to 30 ms and the activation
parameter q=0.25. RP-HPLC with UVand MS detection (LC-
UV-MS) was performed on a Shimadzu Prominence LC-20A
HPLC system equipped with an UV/VIS SPD-20A detector
(ShimadzuCorporation, Kyoto,Japan) andan Alltima C18 RP-
column, 5 μm particle size, inner diameter of 4.6 mm and length
of 150 mm (Alltech, Ridderkerk, Netherlands). The HPLC
system was coupled to a LTQ Orbitrap mass spectrometer
equipped with an Ion Max electrospray ion source (Thermo
Scientiﬁc, Bremen, Germany). The measurements were per-
formed at a ﬂow rate of 1.0 ml/min, which was split in a 33:67
ratio to the UV detector and the ESI-MS. The injection volume
was 20 μl for all runs.
Gradient elution was done with 15% (v/v) ACN in
50 mM ammonium acetate pH 5.0 as solvent A and 60% (v/v)
ACN in 50 mM ammonium acetate pH 5.0 as solvent B. The
ACN concentration was linearly increased from 15% at
0 min, to 20% at 10 min, to 30% at 25 min and ﬁnally to
60% at 35 min. Subsequently, the ACN concentration was
lowered to 15% within 0.1 min and equilibrated for 10 min
prior to the next injection.
MS data were collected in data-dependent mode using
Xcalibur 2.07 software. The precursor ion scan spectra (m/z
300–2,000) were acquired with a resolution of 30,000 at
400 m/z. The most abundant ions were isolated and frag-
mented in the linear ion trap by collisionally induced
dissociation. The resulting fragmentation spectra were
recorded with a LTQ detector. The instrument was calibrated
externally according to the instructions of the manufacturer.
The UV signal at 220 nm of the HPLC efﬂuent was recorded
using LCsolutions softwareversion 1.22 (Shimadzu Corporation,
Kyoto, Japan).
Direct infusion MS analysis of fractions from HP-SEC
and RP-HPLC analysis was performed using a TriVersa
NanoMate robot (Advion BioSystems Inc., Ithaca NY,
USA). The precursor ion scan spectra (m/z 300–2,000) were
acquired with resolution 100,000 at 400 m/z and MS/MS
spectra with resolution 30,000. Fractions from RP-HPLC
were analyzed as collected and after a reduction step.
Reduction was performed by adding 10 mM dithiothreitol
(DTT) in 200 mM ammonium bicarbonate for 10 min at room
temperature. DTT was removed by solid phase extraction
using 200 μl C18 Stage Tips (Proxeon, Odense, Denmark),
wetted with 50% methanol/0.1% formic acid. The samples
were loaded to the wetted Stage Tips, washed with 0.1%
formic acid and eluted in 50% methanol/0.1% formic acid.
RESULTS AND DISCUSSION
Temperature- and pH-dependent Oxytocin Degradation
Kinetics
To study oxytocin degradation a new gradient RP-HPLC
methodhasbeen set-up based ontheEuropeanPharmacopoeia
(13) and the isocratic method described by Chaibva and
Walker (14). The validation showed that the limit of
detection of the developed method for oxytocin was
0.7 ng and the limit of quantiﬁcation 1.4 ng, when using
the conditions as described in Materials and Methods.
Linearity was given from 0.01 to 1.0 mg/ml when working
with an injection volume of 20 μl. The relative standard
deviation over a concentration range of 0.01 to 0.1 mg/ml
was below 0.5% for measurements performed during the
same day, and the day-to-day variation was less than 1.0%.
The impact of temperature and formulation pH on
oxytocin degradation was studied, by monitoring the decrease
in the area of the oxytocin peak (detection 220 nm) by RP-
HPLC with respect to time. Temperatures included in the
study were 40, 55, 70 and 80°C for 0.1 mg/ml oxytocin
formulated in 50 mM phosphate at each of pH 2.0, 4.5, 7.0
and 9.0. Under these conditions adsorption of oxytocin to the
glass vials was not observed and the loss of the oxytocin main
peak could be ascribed to degradation. Depending on the
formulation pH different degradation products were observed
by RP-HPLC (Fig. 1). Interestingly, the disappearance of the
oxytocin peak in RP-HPLC appeared to be (pseudo) ﬁrst
order kinetics at each pH, although various degradation
products were formed. The (pseudo) ﬁrst order kinetics can
be seen from the linear relationship of ln c/c0 *100 versus time
in Fig. 2. The slope of each linear ﬁt (where r
2>0.99) was
determined as the observed degradation rate constant kobs
from which the half life t1/2 in days was calculated (Table I).
As expected, the observed t1/2 decreased with increasing
incubation temperature. The oxytocin formulation at pH 4.5
was most stable at all temperatures.
The degradation of oxytocin as a function of concentra-
tion was tested at 70°C for oxytocin formulated at 0.02 mg/ml,
0.1 mg/ml and 0.5 mg/ml over the pH range of 2.0 to 9.0. At
pH 2.0 the degradation rate constant was clearly concentra-
tion independent (kobs of 0.63 day
−1) and (pseudo) ﬁrst order
kinetics were found for all concentrations (Fig. 3A).
However, for oxytocin formulations of pH 4.5, 7.0 and 9.0
the degradation rates increased with the concentration. This
was particularly obvious for pH 4.5 formulations (Fig. 3B), for
which kobs was 0.314 day
−1 at 0.02 mg/ml, 0.391 day
−1 at
0.1 mg/ml and 0.420 day
−1 at 0.5 mg/ml. For the highest
concentration of 0.5 mg/ml deviation from (pseudo) ﬁrst
order kinetics was evident. This was made more apparent by
plotting the residuals of the linear ﬁts (Fig. 3 C,D). A possible
explanation for the concentration dependency of the
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aggregation competes with other degradation pathways as the
dominant mechanism. Aggregation involves the interaction of
at least two molecules and its progression is generally
accelerated at higher concentrations. Evidence for the
presence of aggregates in heat-stressed formulations is
discussed later. Commercial oxytocin formulations maximally
contain 10 I.U/ml, about 0.015 mg/ml for which aggregation is
not likely to occur.
For the formulations containing 0.1 mg/ml oxytocin we
determined whether the relationship between the observed
degradation rate constant kobs and the temperature obeys the
Arrhenius equation (1),
kobs ¼ Ae
 Ea=RT ð1Þ
where kobs is the degradation rate constant in [day
−1], A is the
pre-exponential factor [day
−1], Ea is the activation energy in
[J mol
−1], R the molar gas constant (8.314472 J K
−1 mol
−1)a n d
T the temperature in [K]. For all formulations studied, the
Arrhenius equation provides a good description of oxytocin
degradation, as is evident from the linearity (r
2>0.99) of the
plots of ln kobs versus 1/T (Fig. 4).
Fig. 2. Degradation of oxytocin over time at 40°C (A), 55°C (B), 70°C (C) and 80°C (D) for formulations with 0.1 mg/ml oxytocin at pH 2.0,
4.5, 7.0 and 9.0 determined by RP-HPLC. Linear ﬁtting (where r
2>0.99) showed the ﬁrst order kinetics, with the slope of the resulting straight
lines representing the degradation rate constant, kobs.
Fig. 1. Example RP-HPLC chromatograms of 0.1 mg/ml oxytocin
standard and stressed formulations in 50 mM phosphate buffer
pH 2.0, 4.5, 7.0 and 9.0 (UV signal at 220 nm) analyzed with mobile
phase of ACN and phosphate buffer. The peaks eluting before 5 min
are not related to oxytocin, but to the buffer.
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calculated using equation (2).
Ea ¼  mR ð2Þ
where m is the slope of the Arrhenius plot [K] and R the
molar gas constant [8.314472 J K
−1 mol
−1].
For pH 4.5 the highest activation energy of 116.3 kJ/mol
was calculated. Our ﬁnding that oxytocin degradation is
slowest at pH 4.5 is in good agreement with the described
stability optimum of oxytocin, i.e. in the pH range between 3
and 5 (5). We compared our results with data on oxytocin
degradation available in the WHO report “Stability of
injectable oxytocics in tropical climates” (4). Therein, the
stability of commercial oxytocin preparations (10 and 5 IU/ml,
corresponding to about 15 and 7.5 μg/ml, respectively formu-
lated at pH 4.0–5.0) was monitored at 4, 21, 30, 40 and 50°C for
2 years by RP-HPLC (4). The WHO data also pointed at
(pseudo) ﬁrst order kinetics for oxytocin degradation. Our
analysis of these published data yielded activation energies of
128±3.8 kJ/mol for 10 IU/ml and 116±5.4 kJ/mol for 5 IU/ml
oxytocin, in excellent agreement with the value obtained for
our formulation at pH 4.5 (116.3 kJ/mol). The WHO data
indicate that Arrhenius behavior can also be assumed for
oxytocin degradation below 40°C. These ﬁndings can facilitate
future formulation development, as the Arrhenius behavior
will allow extrapolation of the degradation kinetics from
accelerated stability testing to lower storage temperatures.
Characterization of Stressed Oxytocin Formulations by UV
Absorption and Fluorescence Spectroscopy
In UV spectroscopy, the formation of aggregates in
oxytocin formulations can be monitored by an overall
increase in optical density. This was the case for heat stressed
oxytocin formulations and was particularly obvious for
oxytocin formulated at pH 4.5, 7.0 and 9.0. An example is
given in Fig. 5A for oxytocin formulated at pH 4.5. The
increase in optical density can be attributed to light scattering
because of the presence of large aggregates. In addition, the
increase in optical density around 320 to 350 nm might in part
be due to the presence of dityrosine (dimeric) species (17).
Dityrosine formation was further conﬁrmed by ﬂuorescence
Table I. Observed Degradation Rate Constants Kobs (n=3) Derived from ln-plots of the Loss of the Main Oxytocin Peak in RP-HPLC from
0.1 mg/ml Oxytocin Formulations Over Time (r
2>0.99) and t1/2 Calculated as ln2/kobs
kobs at 40°C
[day
−1]
t1/2 at 40°C
[days]
kobs at 55°C
[day
−1]
t1/2 at 55°C
[days]
kobs at 70°C
[day
−1]
t1/2 at 70°C
[days]
kobs at 80°C
[day
−1]
t1/2 at 80°C
[days]
pH 2.0 0.033 21.0 0.139 5.0 0.637 1.1 1.153 0.6
pH 4.5 0.006
a 115.5
b 0.046 15.1 0.367
b 1.9
b 1.079
a 0.6
a
pH 7.0 0.080 8.7 0.438 1.6 1.606 0.4 3.594
a 0.2
a
pH 9.0 0.096
a 7.2
a 0.479 1.4 2.212
a 0.3
a 5.913 0.1
The relative standard deviation of three independent degradation experiments was below 5% if not marked otherwise in the table
aRelative standard deviation below 10%
bRelative standard deviation below 15%
Fig. 3. Concentration dependency of degradation over time at 70°C for formulations containing 0.02 mg/ml, 0.1 mg/ml and 0.5 mg/ml oxytocin
at pH 2.0 (A) and pH 4.5 (B) determined by RP-HPLC and the residuals of the linear ﬁt for pH 2.0 (C) and pH 4.5 (D).
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formulations at 340 nm, ﬂuorescence emission could be measured
with a maximum at 410 nm, exemplarily shown for a stressed
pH 4.5 formulation (Fig. 5B). The excitation spectrum was also
found to vary as a function of pH (not shown). This is in line with
behavior that has previously been reported for dityrosine (17).
Oxytocin Aggregation Analyzed by HP-SEC
In HP-SEC the pH of the mobile phase was shown to
inﬂuence signiﬁcantly the separation of oxytocin in certain
stressed formulations. This was particularly obvious for the
stressed pH 2.0 oxytocin formulation (Fig. 6A). When using a
mobile phase with a pH of 5.0, two shoulders were eluting
prior to the monomer peak. RP-HPLC analysis of these
fractions could assign those to deamidated oxytocin i.e. they
corresponded to the peaks eluting prior to the oxytocin peak
in RP-HPLC. This indicates that the separation with a mobile
phase of pH 5.0 was not only based on size, but also on
interactions of chemically changed oxytocin molecules with
the agarose/dextran column material. When lowering the pH
of the mobile phase to 2.0, only one peak was evident by HP-
SEC for stressed pH 2.0 formulations. Fractionation of the
HP-SEC chromatogram and analysis by RP-HPLC proved
that monomeric oxytocin and the deamidated species co-elute
in HP-SEC under acidic conditions. This behavior might be
explained as an effect of electrostatic interactions between
the deamidated peptides and the column. At pH 2.0, the
carboxylic acids in deamidated oxytocin are protonated and
the overall charge of the molecule is zero, whereas at pH 5.0,
the deamidated species will carry a negative charge. For
stressed pH 4.5 (Fig. 6B), 7.0 and 9.0 oxytocin formulations
and for all unstressed formulations (Fig. 6C) the pH of the
mobile phase had less inﬂuence on separation by HP-SEC.
Higher molecular weight species were eluting prior to the
monomer peak independent of the pH of the mobile phase, as
shown for a stressed oxytocin formulation of pH 4.5 in
Fig. 6B. The best separation could be achieved when using a
mobile phase consisting of 30% ACN and 70% 0.04 M formic
acid. In order to prove that the separation was based on size,
fractions were collected from HP-SEC and analyzed by mass
spectrometry. In this way, the main peak eluting at 36 min in
HP-SEC could be attributed to oxytocin monomer ([M+H]
+,
m/z=1,007.44). The HP-SEC UV peak at 26 min was shown
to correspond to oxytocin dimers with a mass of 1,950.892 Da
(charge 2+, m/z=975.446) (see insert in Fig. 6B). The nature
of the dimers is discussed later in this publication.
Mass Spectrometric Identification of Oxytocin Degradation
Products
High resolution ESI-MS and ESI-MS/MS were used to
identify the oxytocin degradation products observed by RP-
HPLC. The analyses were carried out on puriﬁed fractions
corresponding to each of the major degradation peaks for
pH 2.0, as well as by LC-coupled mass spectrometry for
pH 4.5, 7.0 and 9.0 formulations. Simulation of the isotope
Fig. 5. UV absorption spectrum (A) and ﬂuorescence emissions
spectrum after excitation at 340 nm (B) of 0.1 mg/ml oxytocin pH 4.5
unstressed and stressed for 48 h at 70°C.
Fig. 4. Arrhenius plot for 0.1 mg/ml oxytocin formulations at pH 2.0,
4.5, 7.0 and 9.0 calculated from the data of Fig. 2.
1684 Hawe et al.patterns and calculation of the expected masses were done to
verify our assignments.
A number of different degradation mechanisms are
suggested to operate when oxytocin is subjected to thermal
stress, mainly depending upon the formulation pH. In the
stressed pH 2.0 formulations, the four main degradation
peaks eluting before the oxytocin main peak in RP-HPLC
(labeled 1–4i nF i g .1) could be identiﬁed as various
deamidated oxytocin species. Oxytocin contains three possi-
ble deamidation sites: the C-terminal amidated Gly
9, as well
as Asn
5 and Gln
4 in the cyclic portion of the molecule. One
deamidation reaction (R-CONH2 → R-COOH) corresponds
to a mass difference of +0.985 Da. Given differences in m/z
relative to the parent ion of +0.985 for peaks 3 and 4 and
+1.970 for peaks 1 and 2, the compounds were assigned as
mono and bis-deamidated oxytocin, respectively.
In order to be able to elucidate the site(s) of deamidation
within oxytocin, the individual RP-HPLC peak fractions were
collected. The samples were then reduced with DTT to cleave
the disulﬁde linkage, subjected to solid-phase extraction and
analyzed using ESI-MS/MS. By the reduction the oxytocin
molecule is linearized enabling a better identiﬁcation of the
fragmentation ions formed in MS/MS. From the fragmenta-
tion patterns, it was possible to show that peak 1 corre-
sponded to Asn
5 and Gly
9-NH2 deamidation, peak 2 to Gln
4
and Gly
9-NH2 deamidation, peak 3 to Gln
4 deamidation and
peak 4 to deamidation at Gly
9-NH2. A summary of the
fragmentation ions and the analysis is shown in Table II.
Fig. 7A shows the rates of formation of each of the
deamidated species. Gly
9-NH2 deamidates fastest followed by
Gln
4. Bis-deamidated species also form, whereas Asn
5
deamidation is observed only to a minor degree. This might
sound contrary to the literature, where asparagine deamidation
is generally described as being faster than glutamine
deamidation (18). However, within a more complex molecule
like a protein or a peptide the conformation can also impact the
rateandthelikelihoodofdeamidation(19,20).Structuralstudies
onoxytocinhaveshownthatthehydroxylgroupofTyr
2canform
a hydrogenbond with the carboxamideinAsn
5(21,22),bywhich
Asn
5 could become less susceptible to deamidation.
The LC-MS and LC-UV traces in Fig. 8 reveal that there is
little qualitative difference in terms of the oxytocin degradation
products formed upon thermal stress in pH 4.5, 7.0 or 9.0
formulations. The only signiﬁcant difference is the presence of
deamidation peaks in pH 9.0 formulations eluting prior to the
oxytocin main peak in RP-HPLC. However, deamidation at
pH 9.0 is less pronounced as compared to pH 2.0 and generally
stopsatmono-demidatedoxytocin.Thisispresumablyduetothe
different deamidation mechanisms at low and high pH. Above
pH 3 deamidation is thought to proceed via the formation of
cyclic imide intermediates for Asn and Gln, as well as base
catalyzed hydrolysis, whereas proton-catalyzed hydrolysis dom-
inates below pH 3 (9,10,23). It should be remembered that whilst
the degradation proﬁles werecomparable for pH 4.5, 7.0 and 9.0,
the degradation kinetics differed signiﬁcantly as discussed
earlier. In order to reach about 50% degradation in RP-HPLC,
it was necessary to stress oxytocin formulated at pH 4.5 for 48 h
at 70°C, whereas at pH 9.0 only 6 h were needed.
Table III lists the retention times, the m/z of the parent
ion, the charge and the assignment based on LC-MS for the
highest intensity peaks in RP-HPLC identiﬁed in heat stressed
pH 4.5, 7.0 and 9.0 oxytocin formulations (Fig. 8). The main
degradation products were found to be tri- and tetrasulﬁde
bridged oxytocin monomers, and sulfur-linked dimers. The
nature of these dimers will be discussed further below. Larger
aggregates were also observed at the end of the gradient,
although they were not well separated under the used RP-
HPLC conditions. Next to this, a number of minor degradation
Fig. 6. HP-SEC chromatograms of 0.1 mg/ml oxytocin formulations
at pH 2.0 stressed for 24 h at 70°C (A) and at pH 4.5 for 48 h at 70°C
(B) and an unstressed pH 4.5 formulation (C) analyzed with three
mobile phases: 50 mM phosphate, 150 mM NaCl pH 5.0; idem pH 2.0;
and 30% ACN, 70% 0.04 M formic acid. Insert shows the MS results
of the dimer peak measured after fractionation.
1685 Towards Heat-stable Oxytocin Formulationsproducts were identiﬁed, in particular oxidation products either
of cystein or tyrosine. However, these contribute less than 1%
to the total area of all RP-HPLC peaks.
High resolution MS and MS/MS analysis provided
convincing evidence for the assignment of peaks eluting at
19.3 and 23.3 min as tri- and tetrasulﬁde-containing degrada-
tion products, respectively (Fig. 8). The observed differences
in m/z of 31.971 and 63.942 correspond to the addition of one
and two sulfur atoms, respectively, to oxytocin. MS/MS
analysis proved that the sulfur atoms are introduced into the
ring portion of the molecule. The peak at m/z=723.197 for
oxytocin corresponds to a b6 fragment including the cyclic
portion of oxytocin and m/z of 990.430 oxytocin lacking NH3
Table II. Identiﬁcation of Deamidation sites by MS and MS/MS in RP-HPLC Peak Fractions of Heat Stressed Oxytocin Formulations of pH 2.0
Peak MS ion [m/z]
Key fragment ions [m/z]
b6-NH3
a y5 ion
b b4 ion
c Deamidation site
1 (13.7 min) 1,011.13 709.231 504.211 508.221 Asn
6 and Gly
9
2 (14.2 min) 1,011.40 709.232 503.227 509.205 Gln
4 and Gly
9
3 (16.2 min) 1,010.44 709.231 502.243 509.205 Gln
4
4 (16.9 min) 1,010.44 708.248 503.227 508.221 Gly
9
oxytocin (18.8 min) 1,009.46 708.248 502.243 508.221 –
All samples were reduced with DTT
ab6–NH3 fragmentation ion contains the amino acids of the oxytocin ring Cys
1-Tyr
2-Ile
3-Gln
4-Asn
5-Cys
6 missing –NH3 and has a theoretical
mass of 708.25 Da for intact oxytocin
by5-fragmentation ion contains the amino acids Asn
5-Cys
6-Pro
7-Leu
8-Gly
9 and has a theoretical mass of 502.24 Da for intact oxytocin
cb4 fragmentation ion contains the amino acids Cys
1-Tyr
2-Ile
3-Gln
4 and has a theoretical mass of 508.22 Da for intact oxytocin
Fig. 7. Formation of different degradation products at 70°C mea-
sured by RP-HPLC: deamidated species formed at pH 2.0 (A) and
trisulﬁde-, tetrasulﬁde containing oxytocin and dimers formed at
pH 7.0 (B) are shown.
Fig. 8. RP-HPLC with UV (A) and MS (B) detection from heat
stressed pH 4.5, 7.0 and 9.0 samples used for identiﬁcation of
degradation products.
1686 Hawe et al.(Fig. 9A). The b6 fragments for the trisulﬁde (Fig. 9B) and
tetrasulﬁde (Fig. 9C) have a difference in m/z relative to this
of +31.971 and +63.942, due to the introduction of one and
two sulfur atoms, respectively, into the oxytocin ring.
The identiﬁed trisulﬁde- and tetrasulﬁde-containing
oxytocin degradation products are unusual peptides. Whilst
trisulﬁde formation has been reported in the literature as a
thermal decomposition product of the structurally similar
peptide salmon calcitonin (24), this is to our knowledge the
ﬁrst reported instance of a tetrasulﬁde as a degradation
product of a peptide or protein. Trisulﬁdes are known to exist
in nature as they have been observed in variants of
recombinant proteins produced in E. coli like in methionyl
human growth hormone (25), human growth hormone (26)
and a recombinant truncated interleukin-6 mutein (27).
Furthermore, trisulﬁdes have been prepared synthetically, e.g.
also for oxytocin and deaminooxytocin (28). Tetrasulﬁdes can
also be synthesized and are known to be formed as decompo-
sition products following photolysis of cystein (29,30).
The mechanism by which these species form within
oxytocin has not yet been fully elucidated. One possible
explanation is the mechanism reported by Windisch et al.
(1996) for the formation of a trisulﬁde-containing salmon
calcitonin degradation product involving sequential dimeriza-
tion, β-elimination and oxidation (24). A radical-based
mechanism, as described for cystein (29) may also be
postulated. However, this normally requires irradiation with
light of an appropriate wavelength.
For heat stressed oxytocin, two dimeric products were
evident by mass spectrometry, eluting at 24.5 and 28.4 min.
High resolution MS showed the two peaks to be of identical
mass, which corresponds to a sulfur-linked dimeric oxytocin
species that has been doubly deamidated and which has lost
two sulfur atoms through β-elimination. The measured m/z of
975.447 corresponds to the theoretical value of 975.447
calculated for the proposed species. It is difﬁcult to under-
stand why the dimer should be doubly deamidated given that
no deamidation has been observed for monomeric oxytocin at
either pH 4.5 or 7.0. It is postulated that β-elimination may
result from an intramolecular reaction, most probably involving
the Asn
5 side-chain amide. The mechanism of degradation
requires further investigation.
Finally, it is interesting to note from Fig. 7B, that the
concentration of trisulﬁde reaches a maximum after about 8 h
at 70°C and then decreases, whereas the concentration of all
the other degradation products continues to increase. Kinetic
analyses such as these can prove valuable in attempting to
assign reaction mechanisms. A more thorough mechanistic
Table III. Identiﬁcation of Oxytocin Degradation Products for pH 4.5, 7.0 and 9.0 Formulations from LC-MS Data Shown in Fig. 8
Peak number Retention time [min] m/z Charge Assignment
1
a 10.4 1,008.42 1+ Mono-deamidation at Asn
6 or Gln
4a
2
a 12.3 1,008.42 1+ Mono-deamidation at Gly
9a
3
a 12.6 1,008.42 1+ Mono-deamidation at Asn
6 or Gln
4*
4 15.9 1,007.44 1+ Oxytocin
5 19.3 1,039.41 1+ Trisulﬁde
6 23.3 1,071.38 1+ Tetrasulﬁde
7 24.5 975.44 2+ Dimer, bis-deamidated, bis-β-eliminated
8 28.4 975.44 2+ Dimer, bis-deamidated, bis-β-eliminated
9 >30 – multiple Larger aggregates and others
aOnly present in pH 9 samples, assignment based on MS and MS/MS data
Fig. 9. MS/MS results showing the b6-ion (marked with *) from LC-
MS for the oxytocin main peak, retention time 15.9 min, m/z 1,007.44
(A), trisulﬁde-containing oxytocin, retention time 19.3 min, m/z
1,039.42 (B) and tetrasulﬁde-containing oxytocin, retention time
23.3 min, m/z 1,071.39 (C).
1687 Towards Heat-stable Oxytocin Formulationsinvestigation into oxytocin degradation is currently under
investigation.
CONCLUSIONS
Within this study, oxytocin degradation and kinetics
under conditions relevant for pharmaceutical formulations
have been elucidated for the ﬁrst time. From HP-SEC and
RP-HPLC it is obvious that both chemical degradation and
aggregation are dominating degradation mechanisms of
oxytocin at elevated temperatures. The degradation mecha-
nisms of oxytocin depend on the formulation pH. Various
deamidated oxytocin molecules were identiﬁed at pH 2.0 and
pH 9.0. At pH 4.5, 7.0 and 9.0 the formation of tri- and
tetrasulﬁde-containing monomeric oxytocin, different oxyto-
cin dimers and larger aggregates were identiﬁed. Oxytocin
degradation in formulations between pH 2.0 and 9.0 follows
Arrhenius kinetics, with the pH 4.5 formulation being most
stable. This can be beneﬁcial for formulation development as
it can enable the prediction of long-term stability at lower
temperature from accelerated stress testing.
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